Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 9/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CX3CR1 | P49238 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 0.84 |
| ▸ | ESR1 | P03372 | 1/20 | 0.84 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.84 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.84 |
| ▸ | HRH2 | P25021 | 1/20 | 0.84 |
| ▸ | HTR2A | P28223 | 1/20 | 0.84 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolterodine SCHEMBL3098149 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6472968 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL2403972 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL110955 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL467372 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL1560185 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL29873356 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6024199 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL6024194 | 0.98 | CHRM3 (0.96) | CHRM3ADRB2CHRM2CHRM1CHRM5 | |
| Tolterodine SCHEMBL1989702 | 0.93 | CHRM3 (0.88) | CHRM3ADRB2CHRM2CHRM1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4102 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038939-A9 | POROUS PELLETS AND PROCESS OF MANUFACTURING THE SAME | SPI PHARMA, INC. (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119792468-A | Pharmaceutical composition for treating urinary incontinence and preparation method and application thereof | 西安医学院 | 2025-04-11 | — | — | CN | claimed |
| CN-119606905-A | Multi-unit sustained release tablet and preparation method thereof | 南通联亚药业股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2025038939-A1 | POROUS PELLETS AND PROCESS OF MANUFACTURING THE SAME | SPI PHARMA, INC. (US) | 2025-02-20 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-3357945-B1 | ADHESIVE POLYMER AND MEDICAL ADHESIVE PATCH | TEIKOKU SEIYAKU KK (JP) | 2024-10-30 | — | — | EP | claimed |
| US-20240295545-A1 | GLIOMA THERAPY | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-09-05 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-117838662-A | Stable tolterodine tartrate sustained-release capsule and preparation method thereof | 南通联亚药业股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| EP-1364659-A1 | REMEDIES FOR URINARY DISEASES COMPRISING LPA RECEPTOR CONTROLLING AGENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-26 | — | — | EP | claimed |
| US-20030143278-A1 | Vaginal delivery of drugs | FEMMEPHARMA, INC. | 2003-07-31 | — | — | US | claimed |
| US-20030144352-A1 | Antimuscarinic aerosol | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | claimed |
| WO-2003053292-A1 | VAGINAL DELIVERY OF DRUGS | FEMMEPHARMA, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| US-20030095926-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | NOVADEL PHARMA INC. | 2003-05-22 | — | — | US | claimed |
| WO-2003039464-A2 | ANTIMUSCARINIC AEROSOL | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2003026564-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF URINARY DISORDERS | PHARMACIA AB (SE) | 2003-04-03 | — | — | WO | claimed |
| US-20030060513-A1 | Pharmaceutical composition | PHARMACIA AB (SE) | 2003-03-27 | — | — | US | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| CN-1372923-A | Release controlled Tuoteluoding Tartrate and its preparing process | MEIRUI PHARMACEUTICAL CO LTD N (CN) | 2002-10-09 | — | — | CN | claimed |